BCAX

$8.908.61%0.705

Bicara Therapeutics Inc (BCAX)

Bicara Therapeutics Inc Stock (BCAX) Forecast

The Bicara Therapeutics Inc (BCAX) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $5.00, representing a -43.83% decrease from the current price of $8.90. The highest analyst price target is $8.71, and the lowest is $1.29.

Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.

12-Month BCAX Price Target

Average 5.76 (-35.26% Downside)

Is Bicara Therapeutics Inc (BCAX) A Buy Now?

Oscillators

Name	Value	Action
RSI(14)	25.07	Buy
STOCH(9,6)	6.91	Buy
STOCHRSI(14)	31.85	Neutral
MACD(12,26)	-2.95	Sell
ADX(14)	53.92	Sell
William %R	-91.66	Buy
CCI(14)	-82.41	Neutral

Buy: 3 · Sell: 2 · Neutral: 2Summary: Buy

Moving Averages

Period	Simple	Exponential
MA10	10.57 Sell	10.51 Sell
MA20	14.03 Sell	12.95 Sell
MA50	18.16 Sell	16.99 Sell
MA100	22.37 Sell	19.50 Sell
MA200	21.00 Sell	19.69 Sell

Buy: 0 · Sell: 10 · Neutral: 0Summary: Sell

According to our latest analysis, BCAX could be considered a Strong Sell, with 17 technical analysis indicators signaling 3 Buy signals, 12 signaling Sell signals and 2 Neutral signals. This might not be a good time to consider opening new positions on BCAX, as trading bearish markets can be challenging and may result in losses.

RSI (Relative Strength Index): The RSI(14) value of 25.07 indicates that BCAX is oversold. This indicates that BCAX price has experienced a significant decline over a specified lookback period, potentially leading to a rebound.
STOCH (Stochastic Oscillator): The STOCH value of 6.91 indicates that BCAX is oversold. This indicates that BCAX price is at or near the lowest level over a specified lookback period.
STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 31.85 indicates that BCAX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
ADX (Average Directional Index): The ADX value of 53.92 suggests an extremely strong trend in the market. Such high values are relatively rare and indicate a very robust directional movement.
CCI (Commodity Channel Index): A CCI(14) value of -82.41 indicates that BCAX is still oversold but not to an extreme extent.

Long-term BCAX price forecast for 2026, 2030, 2035, 2040, 2045 and 2050

Based on our analysis about Bicara Therapeutics Inc financial reports and earnings history, Bicara Therapeutics Inc (BCAX) stock could reach $16.83 by 2030, $60.62 by 2040 and $86.58 by 2050. See the projected annual prices until 2050 of the Bicara Therapeutics Inc stock below:

Bicara Therapeutics Inc (BCAX) is expected to reach an average price of $10.69 in 2035, with a high prediction of $41.98 and a low estimate of $11.36. This indicates an +20.18% change from the last recorded price of $8.90.
Bicara Therapeutics Inc (BCAX) stock is projected to chart a bullish course in 2040, with an average price target of $16.56, representing an +86.19% change from its current level. The forecast ranges from a conservative $16.62 to a sky-high $60.62.
Our analysts predict Bicara Therapeutics Inc (BCAX) to change +229.18% by 2045, soaring from $29.83 to an average price of $29.28, potentially reaching $72.99. While $29.83 is the low estimate, the potential upside is significant.
Bicara Therapeutics Inc (BCAX) stock is expected to climb by 2050, reaching an average of $48.46, a +444.79% change from its current level. However, a wide range of estimates exists, with high and low targets of $86.58 and $41.93, respectively, highlighting the market's uncertainty.

Bicara Therapeutics Inc Stock (BCAX) Year by Year Forecast

Bicara Therapeutics Inc Stock (BCAX) Price Forecast for 2026

The predicted value for Bicara Therapeutics Inc (BCAX) in 2026 is set at an average of $18.28. Estimates vary from a peak of $30.99 to a trough of $1.29, indicating an +105.54% surge from the present price of $8.90.

Month	Average	Low	High	Change from today's price
December, 2026	$6.92	$1.29	$8.71	-22.22%

Bicara Therapeutics Inc Stock (BCAX) Price Forecast for 2027

For 2027, Stockscan's Analyst expects the average price target for Bicara Therapeutics Inc (BCAX) is $1.88, with a high forecast of $11.52 and a low forecast of $0.000612. This indicates an -78.89% decrease from the last price of $8.90.

Month	Average	Low	High	Change from today's price
January, 2027	$1.70	$1.02	$11.52	-80.84%
February, 2027	$1.58	$0.000612	$6.57	-82.23%
March, 2027	$3.43	$0.3027	$3.83	-61.45%
April, 2027	$1.68	$3.50	$2.96	-81.08%
May, 2027	$1.45	$2.69	$1.80	-83.67%
June, 2027	$3.55	$1.98	$3.29	-60.13%
July, 2027	$0.5595	$0.0305	$2.09	-93.71%
August, 2027	$1.97	$1.06	$3.26	-77.85%
September, 2027	$3.80	$2.65	$3.67	-57.23%
October, 2027	$0.968	$1.78	$2.98	-89.12%
November, 2027	$0.4078	$1.53	$1.36	-95.42%
December, 2027	$1.43	$0.3856	$0.5844	-83.91%

Bicara Therapeutics Inc Stock (BCAX) Price Forecast for 2028

In 2028, Bicara Therapeutics Inc (BCAX) is projected to reach an average price of $11.25, with a high projection of $23.54 and a low estimate of $0.1265. This indicates an +26.45% rise from the last price of $8.90.

Month	Average	Low	High	Change from today's price
January, 2028	$6.85	$0.1265	$8.31	-23.01%
February, 2028	$3.75	$2.67	$6.50	-57.79%
March, 2028	$7.83	$3.69	$9.03	-11.96%
April, 2028	$6.11	$5.53	$8.61	-31.34%
May, 2028	$5.56	$5.09	$8.25	-37.52%
June, 2028	$9.04	$4.09	$9.49	+1.67%
July, 2028	$12.51	$8.29	$12.54	+40.68%
August, 2028	$13.00	$11.71	$15.48	+46.15%
September, 2028	$13.48	$10.42	$15.48	+51.50%
October, 2028	$19.14	$11.07	$20.25	+115.13%
November, 2028	$20.40	$18.96	$23.54	+129.37%
December, 2028	$17.30	$15.82	$21.75	+94.47%

Bicara Therapeutics Inc Stock (BCAX) Price Forecast for 2029

The 2029 price forecast for Bicara Therapeutics Inc Stock (BCAX) is $13.58 on average, with a high prediction of $20.06 and a low estimate of $2.21. This represents an +52.62% increase from the previous price of $8.90.

Month	Average	Low	High	Change from today's price
January, 2029	$16.30	$15.75	$20.06	+83.23%
February, 2029	$11.49	$11.42	$17.20	+29.23%
March, 2029	$3.37	$2.60	$13.08	-62.10%
April, 2029	$9.12	$2.21	$8.78	+2.48%
May, 2029	$9.84	$11.72	$11.05	+10.66%
June, 2029	$14.68	$9.90	$11.58	+65.05%
July, 2029	$13.56	$13.63	$13.24	+52.45%
August, 2029	$18.97	$15.20	$16.23	+113.25%
September, 2029	$16.85	$18.69	$18.41	+89.39%
October, 2029	$16.15	$17.45	$15.80	+81.51%
November, 2029	$17.86	$16.49	$17.61	+100.82%
December, 2029	$14.72	$13.97	$16.22	+65.52%

Bicara Therapeutics Inc Stock (BCAX) Price Forecast for 2030

Bicara Therapeutics Inc Stock (BCAX) is expected to reach an average price of $8.16 in 2030, with a high forecast of $16.83 and a low forecast of $0.4707. This signifies an -8.30% decrease from the last price of $8.90.

Month	Average	Low	High	Change from today's price
January, 2030	$15.44	$14.81	$16.83	+73.59%
February, 2030	$16.90	$16.02	$16.77	+89.97%
March, 2030	$13.69	$14.50	$15.98	+53.86%
April, 2030	$12.66	$13.86	$13.89	+42.28%
May, 2030	$13.30	$12.35	$12.01	+49.56%
June, 2030	$5.21	$6.30	$11.37	-41.42%
July, 2030	$7.27	$6.34	$6.65	-18.26%
August, 2030	$2.82	$3.22	$3.70	-68.32%
September, 2030	$2.41	$3.63	$3.64	-72.93%
October, 2030	$4.25	$3.65	$2.38	-52.27%
November, 2030	$0.3831	$2.73	$3.92	-95.69%
December, 2030	$3.56	$0.4707	$3.59	-60.01%

Similar to BCAX